A question for consideration, OK, Immutep is at the forefront of lag-3 research...
What is to stop Immutep becoming a commercial entity solely aimed at satisfying big pharmas
research requirements in combination therapies in immuno-oncology sector re lag-3 gene....
Any particular research aimed at different indications etc....
Lag-3 IP remains in immutep hands and big pharma commission trials with the funding/payment
to be negotiated?
I could go on and on but I'm sure you get my drift...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 25.0¢ | $537.6K | 2.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40101 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 297079 | 7 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |